Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $123,154.50 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 2,775 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.38, for a total value of $123,154.50. Following the completion of the transaction, the executive vice president now directly owns 34,888 shares of the company’s stock, valued at $1,548,329.44. The trade was a 7.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Andrew Callos also recently made the following trade(s):

• On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The shares were sold at an average price of $45.00, for a total value of $4,500.00.
• On Thursday, March 6th, Andrew Callos sold 3,341 shares of Cytokinetics stock. The shares were sold at an average price of $43.27, for a total value of $144,565.07.

Cytokinetics Price Performance

Shares of Cytokinetics stock opened at $43.45 on Thursday. Cytokinetics, Incorporated has a twelve month low of $40.53 and a twelve month high of $75.71. The stock has a market capitalization of $5.14 billion, a P/E ratio of -8.08 and a beta of 0.95. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The business’s fifty day moving average price is $46.07 and its 200 day moving average price is $50.09.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.26 million. As a group, research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYTK. Jones Financial Companies Lllp boosted its holdings in Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in Cytokinetics in the fourth quarter valued at about $29,000. AlphaQuest LLC raised its position in Cytokinetics by 113,500.0% in the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,135 shares during the period. J.Safra Asset Management Corp raised its position in Cytokinetics by 62.1% in the fourth quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 671 shares during the period. Finally, Blue Trust Inc. raised its position in Cytokinetics by 85.8% in the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 842 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a report on Friday, February 28th. Mizuho increased their target price on Cytokinetics from $99.00 to $103.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Needham & Company LLC reiterated a “buy” rating and set a $72.00 target price on shares of Cytokinetics in a report on Thursday, February 6th. Citigroup assumed coverage on Cytokinetics in a report on Friday, February 7th. They set a “buy” rating and a $86.00 target price on the stock. Finally, Royal Bank of Canada increased their target price on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $82.00.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.